iRhythm Technologies $IRTC Stock Purchased by Stephens Investment Management Group LLC

Stephens Investment Management Group LLC lifted its stake in shares of iRhythm Technologies (NASDAQ:IRTC – Free Report) by 1.7% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 705,533 shares of the company’s stock after buying an additional 12,096 shares during the period. Stephens Investment Management Group LLC’s holdings in iRhythm Technologies were worth $80,191,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of IRTC. Versant Capital Management Inc boosted its holdings in shares of iRhythm Technologies by 123.2% during the 3rd quarter. Versant Capital Management Inc now owns 221 shares of the company’s stock valued at $25,000 after acquiring an additional 122 shares in the last quarter. Rothschild Investment LLC increased its holdings in iRhythm Technologies by 170.0% in the 3rd quarter. Rothschild Investment LLC now owns 216 shares of the company’s stock worth $25,000 after purchasing an additional 136 shares in the last quarter. Global Retirement Partners LLC increased its holdings in iRhythm Technologies by 5,450.0% in the 3rd quarter. Global Retirement Partners LLC now owns 222 shares of the company’s stock worth $25,000 after purchasing an additional 218 shares in the last quarter. Covestor Ltd raised its position in iRhythm Technologies by 44.8% in the third quarter. Covestor Ltd now owns 417 shares of the company’s stock valued at $47,000 after purchasing an additional 129 shares during the last quarter. Finally, Harbor Investment Advisory LLC bought a new position in iRhythm Technologies in the second quarter valued at about $50,000.

Analyst Ratings Changes

A number of analysts have recently commented on IRTC shares. Weiss Ratings lowered iRhythm Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, November 12th. Truist Financial reduced their price target on iRhythm Technologies from $168.00 to $140.00 and set a “buy” rating on the stock in a report on Monday, November 9th. Stephens lowered their price objective on iRhythm Technologies from $160.00 to $120.00 and set an “overweight” rating for the company in a research note on Wednesday, November 11th. Needham & Company LLC dropped their price objective on shares of iRhythm Technologies from $194.00 to $165.00 and set a “buy” rating for the company in a report on Friday, November 6th. Finally, JPMorgan Chase & Co. cut their target price on shares of iRhythm Technologies from $175.00 to $145.00 and set an “overweight” rating on the stock in a research report on Friday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, iRhythm Technologies currently has an average rating of “Moderate Buy” and an average target price of $164.07.

Read Our Latest Stock Report on IRTC

iRhythm Technologies Stock Performance

Shares of iRhythm Technologies stock opened at $94.87 on Thursday. The stock has a market cap of $3.19 billion, a price-to-earnings ratio of 66.91 and a beta of 1.39. iRhythm Technologies has a twelve month low of $82.85 and a twelve month high of $192.47. The company’s fifty day moving average is $109.99 and its 200 day moving average is $119.00. The company has a quick ratio of 3.45, a current ratio of 3.57 and a debt-to-equity ratio of 3.68.

iRhythm Technologies (NASDAQ:IRTC – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.80. The business had revenue of $221.59 million during the quarter, compared to analyst estimates of $222.23 million. iRhythm Technologies had a positive return on equity of 26.88% and a negative net margin of 4.52%. iRhythm Technologies’s revenue for the quarter was up 14.9% compared to the same quarter last year. During the same period last year, the company earned ($0.06) EPS. Sell-side analysts forecast that iRhythm Technologies will post 0.79 EPS for the current year.

iRhythm Technologies announced that its Board of Directors has authorized a stock repurchase plan on Wednesday, November 11th that authorizes the company to repurchase $200 million in outstanding shares. This repurchase authorization authorizes the company to buy up to 6.7% of its shares through open market purchases. Share repurchase plans are often an indication that the company’s board believes its stock is undervalued.

About iRhythm Technologies

(Free Report)

iRhythm Technologies is a medical technology company that develops digital solutions for detecting and monitoring heart rhythm disorders. Its services combine wearable electrocardiogram (ECG) devices with cloud-based data analysis and clinical reporting to help healthcare professionals assess patients for conditions such as cardiac arrhythmias. The company’s Zio product line includes wearable ECG monitors, such as Zio XT, which records a patient’s heart activity during an extended monitoring period. iRhythm also offers Zio AT, a monitoring service designed to provide clinicians with ECG data during the monitoring period.

Featured Stories

Want to see what other hedge funds are holding IRTC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iRhythm Technologies (NASDAQ:IRTC – Free Report).

Institutional Ownership by Quarter for iRhythm Technologies (NASDAQ:IRTC)

Receive News & Ratings for iRhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRhythm Technologies and related companies with MarketBeat.com's FREE daily email newsletter.